Patients Less Than 19 Years of Age
Lumakras will be approved when the following criterion is met:
Member is less than 19 years of age
Authorization will be issued for 12 months.
Non-Small Cell Lung Cancer (NSCLC) — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of non-small cell lung cancer (NSCLC)
Tumor is KRAS G12C-mutation positive
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Non-Small Cell Lung Cancer (NSCLC) — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Pancreatic Adenocarcinoma — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of pancreatic adenocarcinoma
Tumor is KRAS G12C-mutation positive
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Pancreatic Adenocarcinoma — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Authorization will be issued for 12 months.
Ampullary Adenocarcinoma — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of ampullary adenocarcinoma
Tumor is KRAS G12C-mutation positive
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Ampullary Adenocarcinoma — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Colon Cancer — Initial Authorization
Lumakras will be approved when BOTH of the following criteria are met:
BOTH of the following
Diagnosis of colon cancer
Tumor is KRAS G12C-mutation positive
Colon Cancer — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Authorization will be issued for 12 months.
Rectal Cancer — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of rectal cancer
Tumor is KRAS G12C-mutation positive
Rectal Cancer — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Central Nervous System Cancers — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of brain metastases
Metastases from KRAS G12C-mutated positive non-small cell lung cancer
Central Nervous System Cancers — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Authorization will be issued for 12 months.
Small Bowel Adenocarcinoma — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of small bowel adenocarcinoma
Tumor is KRAS G12C-mutation positive
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Small Bowel Adenocarcinoma — Reauthorization
Lumakras will be approved when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Appendiceal Neoplasms and Cancers — Initial Authorization
Lumakras will be approved when ALL of the following criteria are met:
ALL of the following
Diagnosis of appendiceal neoplasm or cancer
Tumor is KRAS G12C-mutation positive
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Initial Therapy
The initial therapy criterion is:
Patient has received at least one prior systemic therapy (e.g., immune checkpoint inhibitor, platinum-based chemotherapy)
Reauthorization
Lumakras will be approved for reauthorization when the following continuation criterion is met:
Patient does not show evidence of progressive disease while on Lumakras therapy
Authorization will be issued for 12 months.
NCCN Recommended Regimens
Lumakras is covered when the following criterion is met:
The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B